Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
about
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsEosinophilia in Hematologic DisordersBCR-JAK2 drives a myeloproliferative neoplasm in transplanted mice.KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11)A t(8;9)(p22;p24)/PCM1-JAK2 translocation in a patient with myeloproliferative neoplasm and myeloid sarcoma: first report in Korea.World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma.Atypical chronic myeloid leukemia: a rare entity with management challenges.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.Guideline for the investigation and management of eosinophilia.
P2860
Q26782539-49E00292-5400-4F8F-9527-8093A47902CDQ26799611-966F262A-D916-4070-8EB6-B61854857D2CQ34461890-91AE9F04-3090-415B-BCBE-C1E56B736144Q34478126-FA3C144F-5468-4BC0-8063-20B6635BE6C9Q34556842-82E305E9-63D3-498A-861C-30A54222501BQ38400828-6047F78D-ABB4-4B44-B03E-6EF18BFD3568Q41906538-762DE12A-2779-49CE-8A44-2936BBE224FBQ43109575-5C884E36-4AB1-4FBD-918D-75F64F9D2D97Q46026437-97DFDF7F-D8DE-48DF-9C36-3F354BE05976Q47270193-0251D096-E199-43FA-9A10-83DCA6AF6089Q47789741-9F3ECF7F-4AF5-411D-ACC1-B454471DA5A9Q48109284-3FA972CB-3762-4BCD-87E2-DFC7528102DFQ49536138-6772E03F-5A4C-47C5-8C3B-0BE2A37D309EQ49712787-E34F1DC3-40C2-4797-BAF3-43DF588232EAQ52887806-3573F72C-17D5-405C-96DA-17918B5384D7Q54114931-70D7F2B6-8C1C-4450-A8FD-E0F739F5AB4AQ55059996-6443702F-4FA1-4AA6-9B9F-57A950E24A45
P2860
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Limited duration of complete r ...... AK2 and BCR-JAK2 fusion genes.
@en
Limited duration of complete r ...... AK2 and BCR-JAK2 fusion genes.
@nl
type
label
Limited duration of complete r ...... AK2 and BCR-JAK2 fusion genes.
@en
Limited duration of complete r ...... AK2 and BCR-JAK2 fusion genes.
@nl
prefLabel
Limited duration of complete r ...... AK2 and BCR-JAK2 fusion genes.
@en
Limited duration of complete r ...... AK2 and BCR-JAK2 fusion genes.
@nl
P2093
P50
P1433
P1476
Limited duration of complete r ...... AK2 and BCR-JAK2 fusion genes.
@en
P2093
Andreas Reiter
Andrew Chase
Hans-Peter Horny
Joannah Score
Juliana Schwaab
Katherine Waghorn
Marcin Knut
Mohamad Jawhar
Nicole Naumann
William Tapper
P304
P356
10.1007/S00277-014-2221-Y
P577
2014-09-27T00:00:00Z